+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Bone Cancer Drugs Market 2019-2023 - Product Image

Global Bone Cancer Drugs Market 2019-2023

  • ID: 4769207
  • Report
  • April 2019
  • Region: Global
  • 125 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Amgen
  • Bayer AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • MORE
Increasing strategic alliance will drive the market growth in the forecast period. Small and medium sized pharmaceutical and biotechnology vendors in the market face lack of funding to complete clinical trial and launch the drugs for the treatment of various bone cancer indications. Pharmaceutical players face challenges with the distribution of drugs in the regions where the vendor does not operate. To overcome such challenge, these pharmaceutical companies are entering into strategic alliance with local pharmaceutical vendors for manufacturing and distribution of drugs. The analysts have predicted that the bone cancer drugs market will register a CAGR of nearly 12% by 2023.

Market Overview

Growing risk factors

Growing risk factors associated with bone cancer will drive the market growth in the forecast period. The growing prevalence of specific cancers, where radiation therapy has been a dominant treatment, is further stimulating the market growth. Factors such as old age and the family history of bone cancer are common risk factors for the disease.

Preference of surgery

The most preferred treatment options available to patients with bone cancer, is surgeries, due to their remissive nature. Surgery for bone cancer involves wide excision of the tumor, which includes removal of the tumor along with a part of healthy tissue around the tumor in all directions. The higher probability of recurrence of cancer tumors in the future reduces patient adherence to drug treatment landscape which poses a challenge to the market growth.

For the detailed list of factors that will drive and challenge the growth of the bone cancer drugs market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be concentrated and with the presence of few companies. Factors such as the growing risk factors and increasing strategic alliance, will provide considerable growth opportunities to bone cancer drugs manufactures. Amgenm, Bayer AG, Bristol-Myers Squibb Company, Merck & Co. Inc., and Pfizer Inc. are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen
  • Bayer AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
Preface
Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY INDICATION
  • Market segmentation by indication
  • Comparison by indication
  • Osteosarcoma - Market size and forecast 2018-2023
  • Ewing's sarcoma - Market size and forecast 2018-2023
  • Chondrosarcoma - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by indication
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • Pfizer Inc.
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of vendors classification
List of Exhibits
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global bone cancer drugs market pipeline: Overview
Exhibit 18: Global bone cancer drugs market pipeline: Snapshot
Exhibit 19: Indication - Market share 2018-2023 (%)
Exhibit 20: Comparison by indication
Exhibit 21: Osteosarcoma - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Osteosarcoma - Year-over-year growth 2019-2023 (%)
Exhibit 23: Ewing's sarcoma - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Ewing's sarcoma - Year-over-year growth 2019-2023 (%)
Exhibit 25: Chondrosarcoma - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Chondrosarcoma - Year-over-year growth 2019-2023 (%)
Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by indication
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in North America
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Amgen - Vendor overview
Exhibit 54: Amgen - Business segments
Exhibit 55: Amgen - Organizational developments
Exhibit 56: Amgen - Geographic focus
Exhibit 57: Amgen - Key offerings
Exhibit 58: Amgen - Key customers
Exhibit 59: Bayer AG - Vendor overview
Exhibit 60: Bayer AG - Business segments
Exhibit 61: Bayer AG - Organizational developments
Exhibit 62: Bayer AG - Geographic focus
Exhibit 63: Bayer AG - Segment focus
Exhibit 64: Bayer AG - Key offerings
Exhibit 65: Bayer AG - Key customers
Exhibit 66: Bristol-Myers Squibb Company - Vendor overview
Exhibit 67: Bristol-Myers Squibb Company - Business segments
Exhibit 68: Bristol-Myers Squibb Company - Organizational developments
Exhibit 69: Bristol-Myers Squibb Company - Geographic focus
Exhibit 70: Bristol-Myers Squibb Company - Key offerings
Exhibit 71: Bristol-Myers Squibb Company - Key customers
Exhibit 72: Merck & Co. Inc. - Vendor overview
Exhibit 73: Merck & Co. Inc. - Business segments
Exhibit 74: Merck & Co. Inc. - Organizational developments
Exhibit 75: Merck & Co. Inc. - Geographic focus
Exhibit 76: Merck & Co. Inc. - Segment focus
Exhibit 77: Merck & Co. Inc. - Key offerings
Exhibit 78: Merck & Co. Inc. - Key customers
Exhibit 79: Pfizer Inc. - Vendor overview
Exhibit 80: Pfizer Inc. - Business segments
Exhibit 81: Pfizer Inc. - Organizational developments
Exhibit 82: Pfizer Inc. - Geographic focus
Exhibit 83: Pfizer Inc. - Segment focus
Exhibit 84: Pfizer Inc. - Key offerings
Exhibit 85: Pfizer Inc. - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of vendors classification
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Amgen
  • Bayer AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • MORE
Global Bone Cancer Drugs Market 2019-2023

The analyst recognizes the following companies as the key players in the global bone cancer drugs market: Amgenm, Bayer AG, Bristol-Myers Squibb Company, Merck & Co. Inc., and Pfizer Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the novel drug delivery.”

According to the report, one of the major drivers for this market is the growing risk factors.

Further, the report states that one of the major factors hindering the growth of this market is the preference of surgery.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Amgen
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll